All In Biotech

Drug Trial Radar · NCT05180240

Impact of CardiolRx on Myocardial Recovery in Patients With Acute Myocarditis

Impact of CardiolRx on Myocardial Recovery in Acute Myocarditis. A Double-blind, Placebo-controlled Trial

Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 109 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

109

Actual

Start

Jul 28, 2022

Primary completion

Jan 31, 2025

Study completion Feb 4, 2025

Sponsor

Lead sponsor
Cardiol Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Jan 6, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multi-center, double-blind, placebo-controlled, parallel group design. Patients with myocarditis will be screened and, if eligible, randomized within 10 days of the diagnostic CMR to CardiolRx or placebo. CardiolRx is pharmaceutically produced Cannabidiol and is free of tetrahydrocannabinol (THC\<5 ppm). The treatment period is 12 weeks; a last follow-up visit is scheduled one week after the last treatment, 13 weeks after randomization. Study assessments include Cardiac Magnetic Resonance imaging (CMR), ECG monitoring, the Kansas City Cardiomyopathy Questionnaire (KCCQ), the Columbia-Suicide Severity Rating Scale (C-SSRS) as well as physical exams and laboratory tests. The primary and secondary outcome parameters are measured by CMR. Additional outcomes include clinical endpoints and changes in inflammatory and biomarkers.

Conditions

  • Acute Myocarditis

Interventions

  • CardiolRxDrug

    Eligible patients will be randomized to receive CardiolRx or placebo. Intervention will be administered orally (via syringe) with food twice daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Extracellular Volume (ECV)Time frame: 12 weeks post randomization
  2. Global Longitudinal Strain (GLS)Time frame: 12 weeks post randomization

Locations

37 sites in 5 countries. Site status is shown where the registry gives one.

  • MedStar Heart and Vascular Institute

    Washington D.C., District of Columbia

  • Massachusetts General Hospital site

    Boston, Massachusetts

  • Minneapolis Heart Institute Foundation

    Minneapolis, Minnesota

  • Cleveland Clinic

    Cleveland, Ohio

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • Virginia Commonwealth University

    Richmond, Virginia

  • Hospital Felicio Rocho - Fundação Felice Rosso

    Belo Horizonte, Brazil

  • Hospital Angelina Caron

    Campina Grande do Sul, Brazil

  • Hospital São Lucas

    Porto Alegre, Brazil

  • Instituto D´Or de Pesquisa e Ensino

    Rio de Janeiro, Brazil

  • Hospital Pró-Cardíaco

    Rio de Janeiro, Brazil

  • Hospital Regional de São José

    São José, Brazil

  • Irmandade da Santa Casa de Misericórdia de São Paulo

    São Paulo, Brazil

  • Instituto do Coração - InCor

    São Paulo, Brazil

  • Nupec-Orizonti

    Belo Horizonte, Minas Gerais, Brazil

  • PUC trials

    Curitiba, Paraná, Brazil

  • Complexo Hospitalar de Niterói

    Niterói, Rio de Janeiro, Brazil

  • Hospital Moinhos de Vento

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital de Clínicas de Porto Alegre (HCPA)

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital Nove de Julho

    São Paulo, São Paulo, Brazil

  • University of Alberta Hospital

    Edmonton, Alberta, Canada

  • McGill University Health Centre

    Montreal, Quebec, Canada

  • Hopital Louis Pradel Hospices Civils de Lyon

    Bron, France

  • CHU de Montpellier

    Montpellier, France

  • Centre Hospitalier Universitaire de Nîmes

    Nîmes, France

  • Hôpital Lariboisière - Département de Cardiologie

    Paris, France

  • Hopital Bichat Claude Bernard

    Paris, France

  • Hôpital européen Georges-Pompidou

    Paris, France

  • Institut de Cardiologie hopital Pitié Salpêtrière

    Paris, France

  • Centre Hospitalier Universitaire de Poitiers

    Poitiers, France

  • Hôpital Foch

    Suresnes, France

  • Chu Rangueil

    Toulouse, France

  • Barzilai Medical Center

    Ashkelon, Israel

  • Shaare Zedek Medical Center

    Jerusalem, Israel

  • Beilinson Hospital, Rabin medical Center

    Petah Tikva, Israel

  • Tel Aviv Sourasky Medical Center (Ichilov)

    Tel Aviv, Israel

  • Shamir Medical Center (Assaf Harofeh)

    Zrifin, Israel

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.